Milestone Payments Earned by Orexigen Total $100 Million as Contrave® (naltrexone HCI and bupropion HCI extended release) is Shipped to Wholesalers in Preparation for Commercial Launch
October 15, 2014Orexigen receives $70 million milestone payment from Takeda Pharmaceuticals for preparation for the commercial launch of Contrave®. The company received $30 million from Takeda in September upon FDA approval.
More »
Atara Biotherapeutics Announces Pricing of Its Initial Public Offering
October 15, 2014Atara Biotherapeutics announced the pricing of its initial public offering of 5,000,000 shares of common stock at $11.00 per share. Shares begin trading on NASDAQ under the ticker symbol “ATRA” on October 16, 2014.
More »
Dicerna Presents Preclinical Data for Investigational RNAi Therapeutic DCR-PH1 in Primary Hyperoxaluria Type 1 (PH1) at the 10th Annual Meeting of the Oligonucleotide Therapeutics Society
October 14, 2014Dicerna Pharmaceuticals presented data from its RNAi Therapeutic DCR-PH1, the company’s investigational treatment for PH1, a rare liver disorder, at the Meeting of the Oligonucleotide Therapeutics Society (OTS).
More »